• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

MHRA issues warning on Ubertan nasal spray

The UK Medicines and Healthcare products Regulatory Agency (MHRA) is warning consumers against using a “fake tan nasal spray” marketed as Ubertan. According to the agency, the product comes in two versions, one of which contains “melanotan II, an unlicensed medicine with no evidence of safety, quality or that it works, and with unknown side effects” and another that claims to contain an extract of coleus forskohlii, which the agency says has an active ingredient that acts on the enzyme adenylate cyclase, which activates Cyclic Adenosine Monophosphate (cAMP).

The MHRA says the product is being sold illegally as a tanning agent in beauty salons, gyms, and online. It has contacted seven retailers about illegal sales of Ubertan and is providing ways for consumers to report other sellers anonymously.

MHRA Head of the Medicines Borderline Section, David Carter, advised consumers, “Putting your health on the line just in order to get a tan is just really not worth the risk. None of these products have been clinically tested and as a result there is no way of knowing just how serious the side effects could be, or the impact on your health. If you have this product at home do not use it again, throw it in the bin. And if you have used it and you have concerns then speak to your GP.”

Read the MHRA press release.

Share

published on August 3, 2011

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews